The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Stereotactic radiosurgery (SRS): Treatment option for recurrent glioblastoma multiforme (GBM)
Open accessAbstract
BACKGROUND: This article describes the results of a study of stereotactic radiosurgery (SRS) in the treatment of patients with recurrent malignant glioma. METHODS: Thirty‐two patients with recurrent glioblastoma multiforme (GBM) were treated for 36 lesions with SRS from 1993 to 2001. Nineteen patients were male and 13 were female. The median age at primary diagnosis of the tumor was 56 years (range, 33–76 yrs). At the time of initial diagnosis a total neurosurgical resection was performed in 7, a subtotal resection in 21, and a biopsy in 4 patients. Histology evaluations revealed glioblastoma multiforme (WHO Grade IV) in all 32 patients. In all patients radiotherapy was performed as the first‐line therapy, applied as fractionated external beam radiotherapy. The median interval between primary irradiation and reirradiation was 10 months. The median dose applied was 15 Gy (range, 10–20 Gy) prescribed to the 80% isodose line that encompassed the target volume. No concomitant chemotherapy was applied. RESULTS: Treatment was well tolerated by all patients. No acute toxicities > CTC Grade II occurred. No severe long‐term toxicities including radionecrosis were observed. The median follow‐up time was 13 months (range, 1–89 mo). All patients died of tumor progression during follow‐up. The median overall survival from primary diagnosis of the tumor was 22 months (range, 9–133 mo). The survival rate at 1 year was 90%, and 49% and 26% at 2 and 3 years, respectively. Median overall survival after SRS was 10 months. At 6 and 12 months after SRS, survival rates were 72% and 28%, respectively. Median progression‐free survival after SRS was 7 months. CONCLUSIONS: SRS offers effective treatment as a salvage therapy for a subgroup of patients with smaller lesions of recurrent GBM. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×
“After treatment with temozolomide, 6 months progression-free survival rates of 46 – 60% can be found in the literature.(34,35) Surgical resections may be possible in some patients.”
Background
Cited by
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Recurrent glioblastoma multiforme: a review of natural history and management options
Hou, L. C., Veeravagu, A., Hsu, A. R., & Tse, V. C. K. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.2 · Cited by 275
Metadata
- Authors
- Combs, S. E., Widmer, V., Thilmann, C., Hof, H., Debus, J., & Schulz‐Ertner, D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-10-11
- Volume
- 104
- Issue
- 10
- Pages
- 2168-2173
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1485654067
- Cited by
- 217
- References
- 1
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic radiosurgery (SRS): Treatment option for recurrent glioblastoma multiforme (GBM). https://app.cochat.ai/papers/10.1002/cncr.21429
- The paper
- Combs, S. E., Widmer, V., Thilmann, C., Hof, H., Debus, J., & Schulz‐Ertner, D. (2005). Stereotactic radiosurgery (SRS): Treatment option for recurrent glioblastoma multiforme (GBM). Cancer. https://doi.org/10.1002/cncr.21429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.